Delveinsight brings you the comparative analysis on Positive Phase III trial results of PARP inhibitors, Zejula (Niraparib) and Lynparza (Olaparib) in metastatic CRPC patient population.
PARP inhibitors are one of the most promising therapeutic classes in the phase III pipeline, based on the demonstrated effectiveness of Olaparib (Lynparza; AstraZeneca) and Rucaparib (Rubraca; Clovis Oncology) in Prostate Cancer. Two PARP inhibitors, Rucaparib, and Olaparib have already received FDA approval in May 2020 for use in mCRPC in later line settings, however we still await to see the approval of PARP inhibitors in the first line setting of mCRPC. AstraZeneca and Merck are...
